Evommune Announces $125 Million Private Placement Financing

Evommune, Inc. ( (EVMN) ) just unveiled an announcement.

On February 12, 2026, Evommune, Inc. entered into a securities purchase agreement to sell 4,494,279 shares of its common stock at $27.88 per share in a private placement to a select group of new and existing mutual funds and dedicated healthcare institutional investors, for expected gross proceeds of approximately $125 million. The private placement, which relies on a registration exemption and is expected to close around February 17, 2026, will see Evommune use the net proceeds to advance its clinical development programs and for general corporate purposes, supported by a registration rights agreement to facilitate future resale of the shares.

The most recent analyst rating on (EVMN) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Evommune, Inc. stock, see the EVMN Stock Forecast page.

Spark’s Take on EVMN Stock

According to Spark, TipRanks’ AI Analyst, EVMN is a Neutral.

The score is primarily held down by weak financial performance: widening losses, accelerating cash burn, and a highly leveraged balance sheet with negative equity. Technicals provide some offset with positive near-term momentum (price above DMA20 and positive MACD), but valuation cannot be meaningfully assessed due to missing P/E and dividend yield data.

To see Spark’s full report on EVMN stock, click here.

More about Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies that target key drivers of chronic inflammatory diseases. The company aims to improve patients’ daily lives and prevent long-term effects of uncontrolled inflammation by advancing a portfolio of differentiated product candidates in this therapeutic area.

Average Trading Volume: 514,820

Current Market Cap: $897.2M

Learn more about EVMN stock on TipRanks’ Stock Analysis page.